SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 145.05 |
| Enterprise Value ($M) | 126.82 |
| Book Value ($M) | 54.91 |
| Book Value / Share | 0.61 |
| Price / Book | 2.64 |
| NCAV ($M) | 45.92 |
| NCAV / Share | 0.51 |
| Price / NCAV | 3.16 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.25 |
| Return on Assets (ROA) | -0.12 |
| Return on Equity (ROE) | -0.22 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.26 |
| Current Ratio | 5.26 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 106.00 |
| Assets | 115.00 |
| Liabilities | 60.08 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 27.86 |
| Operating Income | -14.89 |
| Net Income | -14.23 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 49.60 |
| Cash from Investing | -46.25 |
| Cash from Financing | 0.55 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Bristol Myers Squibb Co | 2.06 | -61.32 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 30,077 | 139,548 | 21.55 | |
| 65,370 | 256,830 | 25.45 | |
| 40,842 | 244,721 | 16.69 | |
| 85,398 | 532,622 | 16.03 | |
| 122,520 | 398,561 | 30.74 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CDXC – ChromaDex Corporation | CELU – Celularity Inc. |
| CELZ – Creative Medical Technology Holdings, Inc. | CING – Cingulate Inc. |
| CKPT – Checkpoint Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io